Tags

Type your tag names separated by a space and hit enter

Effectiveness and tolerability of switching to aripiprazole from risperidone in subjects with autism spectrum disorders: a prospective open-label study.
Clin Neuropharmacol. 2013 Sep-Oct; 36(5):151-6.CN

Abstract

BACKGROUND

Subjects with autism spectrum disorders (ASDs) often exhibit behavioral symptoms such as aggressiveness and irritability. The purpose of this study was to examine the efficacy and the tolerability of aripiprazole switched from risperidone in children and adolescents with ASD.

METHODS

This prospective, 12-week, open-label study included 9 male subjects with ASD (age range, 9-22 years; mean ± SD age, 14.8 ± 4.0 years) followed up for 12 weeks after switching to aripiprazole from risperidone. The primary outcome measures were the Clinical Global Impression-Improvement scales and the irritability subscale of the Aberrant Behavior Checklist.

RESULTS

The mean ± SD maintenance dosages of risperidone and aripiprazole were 0.6 ± 0.4 mg/d and 4.8 ± 4.0 mg/d, respectively. The mean ± SD scores of the irritability subscale of the Aberrant Behavior Checklist before switching to aripiprazole (baseline) and 12 weeks after switching to aripiprazole (end point) were 14.8 ± 7.6 and 13.1 ± 8.0, respectively. The mean ± SD Clinical Global Impression-Improvement score, a comparison from baseline to end point, was 2.4 ± 0.7. Mild somnolence was observed only in 1 subject. No significant changes in vital signs, weight, electrocardiogram, or laboratory measures occurred during switching to aripiprazole. Serum prolactin levels decreased significantly from 17.3 ± 9.4 ng/mL (baseline) to 2.3 ± 1.7 ng/mL (end point).

CONCLUSIONS

The results show that aripiprazole might be generally well tolerated and might constitute an alternative treatment of subjects with ASD who experience poor efficacy or tolerability issues with risperidone treatment. Additional long-term controlled studies are needed to evaluate the efficacy and the safety of switching to aripiprazole from other antipsychotics in subjects with ASD.

Authors+Show Affiliations

*Department of Neuropsychiatry, University of Fukui, Fukui, Japan; †Hiratani Child Development Clinic, Fukui, Japan; ‡Research Center for Child Mental Development, University of Fukui, Fukui, Japan; and§Faculty of Nursing and Social Welfare Sciences, Fukui Prefectural University, Fukui, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

24045605

Citation

Ishitobi, Makoto, et al. "Effectiveness and Tolerability of Switching to Aripiprazole From Risperidone in Subjects With Autism Spectrum Disorders: a Prospective Open-label Study." Clinical Neuropharmacology, vol. 36, no. 5, 2013, pp. 151-6.
Ishitobi M, Kosaka H, Takahashi T, et al. Effectiveness and tolerability of switching to aripiprazole from risperidone in subjects with autism spectrum disorders: a prospective open-label study. Clin Neuropharmacol. 2013;36(5):151-6.
Ishitobi, M., Kosaka, H., Takahashi, T., Yatuga, C., Asano, M., Tanaka, Y., Ueno, K., Okazaki, R., Omori, M., Hiratani, M., Tomoda, A., & Wada, Y. (2013). Effectiveness and tolerability of switching to aripiprazole from risperidone in subjects with autism spectrum disorders: a prospective open-label study. Clinical Neuropharmacology, 36(5), 151-6. https://doi.org/10.1097/WNF.0b013e3182a31ec0
Ishitobi M, et al. Effectiveness and Tolerability of Switching to Aripiprazole From Risperidone in Subjects With Autism Spectrum Disorders: a Prospective Open-label Study. Clin Neuropharmacol. 2013 Sep-Oct;36(5):151-6. PubMed PMID: 24045605.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effectiveness and tolerability of switching to aripiprazole from risperidone in subjects with autism spectrum disorders: a prospective open-label study. AU - Ishitobi,Makoto, AU - Kosaka,Hirotaka, AU - Takahashi,Tetsuya, AU - Yatuga,Chiho, AU - Asano,Mizuki, AU - Tanaka,Yuji, AU - Ueno,Kanji, AU - Okazaki,Ryoko, AU - Omori,Masao, AU - Hiratani,Michio, AU - Tomoda,Akemi, AU - Wada,Yuji, PY - 2013/9/19/entrez PY - 2013/9/21/pubmed PY - 2014/4/22/medline SP - 151 EP - 6 JF - Clinical neuropharmacology JO - Clin Neuropharmacol VL - 36 IS - 5 N2 - BACKGROUND: Subjects with autism spectrum disorders (ASDs) often exhibit behavioral symptoms such as aggressiveness and irritability. The purpose of this study was to examine the efficacy and the tolerability of aripiprazole switched from risperidone in children and adolescents with ASD. METHODS: This prospective, 12-week, open-label study included 9 male subjects with ASD (age range, 9-22 years; mean ± SD age, 14.8 ± 4.0 years) followed up for 12 weeks after switching to aripiprazole from risperidone. The primary outcome measures were the Clinical Global Impression-Improvement scales and the irritability subscale of the Aberrant Behavior Checklist. RESULTS: The mean ± SD maintenance dosages of risperidone and aripiprazole were 0.6 ± 0.4 mg/d and 4.8 ± 4.0 mg/d, respectively. The mean ± SD scores of the irritability subscale of the Aberrant Behavior Checklist before switching to aripiprazole (baseline) and 12 weeks after switching to aripiprazole (end point) were 14.8 ± 7.6 and 13.1 ± 8.0, respectively. The mean ± SD Clinical Global Impression-Improvement score, a comparison from baseline to end point, was 2.4 ± 0.7. Mild somnolence was observed only in 1 subject. No significant changes in vital signs, weight, electrocardiogram, or laboratory measures occurred during switching to aripiprazole. Serum prolactin levels decreased significantly from 17.3 ± 9.4 ng/mL (baseline) to 2.3 ± 1.7 ng/mL (end point). CONCLUSIONS: The results show that aripiprazole might be generally well tolerated and might constitute an alternative treatment of subjects with ASD who experience poor efficacy or tolerability issues with risperidone treatment. Additional long-term controlled studies are needed to evaluate the efficacy and the safety of switching to aripiprazole from other antipsychotics in subjects with ASD. SN - 1537-162X UR - https://www.unboundmedicine.com/medline/citation/24045605/Effectiveness_and_tolerability_of_switching_to_aripiprazole_from_risperidone_in_subjects_with_autism_spectrum_disorders:_a_prospective_open_label_study_ L2 - http://dx.doi.org/10.1097/WNF.0b013e3182a31ec0 DB - PRIME DP - Unbound Medicine ER -